November 19, 2019

Andre Turenne
Chief Executive Officer
Voyager Therapeutics, Inc.
75 Sidney Street
Cambridge, MA 02139

       Re: Voyager Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed on November 6, 2019
           File No. 333-234527

Dear Mr. Turenne:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this comment, we may have additional comments.

Registration Statement on Form S-3, filed on November 6, 2019

Exclusive Forum Selection, page 25

1.     We note that your exclusive forum selection identifies the Court of
Chancery of the State
       of Delaware as the exclusive forum for certain litigation, including any
"derivative
       action." Please disclose whether this provision applies to actions
arising under the
       Securities Act or the Exchange Act. In that regard, we note that Section
27 of the
       Exchange Act creates exclusive federal jurisdiction over all suits
brought to enforce any
       duty or liability created by the Exchange Act or the rules and
regulations thereunder, and
       Section 22 of the Securities Act creates concurrent jurisdiction for
federal and state courts
       over all suits brought to enforce any duty or liability created by the
Securities Act or the
       rules and regulations thereunder. If the provision applies to Securities
Act claims, please
       revise your prospectus to state that there is uncertainty as to whether
a court would
       enforce such provision and investors cannot waive compliance with the
federal securities
 Andre Turenne
Voyager Therapeutics, Inc.
November 19, 2019
Page 2
      laws and the rules and regulations thereunder. If the provision does not
apply to actions
      arising under the Securities Act or Exchange Act, please also tell us how
you will inform
      investors in future filings that the provision does not apply to any
actions arising under the
      Securities Act or Exchange Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Paul Fischer, Staff Attorney, at 202-551-3415, or Celeste
M. Murphy,
Legal Branch Chief, at 202-551-3257, with any questions.



                                                             Sincerely,
FirstName LastNameAndre Turenne
                                                             Division of
Corporation Finance
Comapany NameVoyager Therapeutics, Inc.
                                                             Office of Life
Sciences
November 19, 2019 Page 2
cc:       Brian Johnson, Esq.
FirstName LastName